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Abstract Input estimation is employed in cases where it
is desirable to recover the form of an input function which
cannot be directly observed and for which there is no
model for the generating process. In pharmacokinetic and
pharmacodynamic modelling, input estimation in linear
systems (deconvolution) is well established, while the
nonlinear case is largely unexplored. In this paper, a rig-
orous definition of the input-estimation problem is given,
and the choices involved in terms of modelling assump-
tions and estimation algorithms are discussed. In particular,
the paper covers Maximum a Posteriori estimates using
techniques from optimal control theory, and full Bayesian
estimation using Markov Chain Monte Carlo (MCMC)
approaches. These techniques are implemented using the
optimisation software CasADi, and applied to two example
problems: one where the oral absorption rate and
bioavailability of the drug eflornithine are estimated using
pharmacokinetic data from rats, and one where energy
intake is estimated from body-mass measurements of mice
exposed to monoclonal antibodies targeting the fibroblast
growth factor receptor (FGFR) 1c. The results from the
analysis are used to highlight the strengths and weaknesses
of the methods used when applied to sparsely sampled data.
The presented methods for optimal control are fast and
robust, and can be recommended for use in drug discovery.
The MCMC-based methods can have long running times
and require more expertise from the user. The rigorous
definition together with the illustrative examples and sug-
gestions for software serve as a highly promising starting
point for application of input-estimation methods to prob-
lems in drug discovery.
Keywords Input estimation  Deconvolution  Nonlinear
dynamic systems  Optimal control  Markov Chain Monte
Carlo method
Introduction
Pharmacokinetic and pharmacodynamic (PKPD)models are
generally represented using a system of ordinary differential
equations (ODEs). The structure and parameter values are
usually estimated from experimental data. In some cases, it is
useful to estimate the time-course of a variable evenwhen no
generating model is available. This can be done using
experimental data combined with a model connecting the
sought variablewith themeasurements. This paper addresses
one such case: estimating the unknown input function to a
known dynamical system, given sparse measurements of
certain state variables (Fig. 1).
A typical example is to estimate the oral absorption-rate
of a drug, given measurements of the drug plasma con-
centration. This assumes that a model of drug distribution
and elimination is available. Of particular interest is the
oral bioavailability—the fraction of the drug that is
absorbed [22]. Clearly, this also applies to other routes of
administration, e.g. subcutaneous. Another example is to
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estimate the energy intake of a subject given body-mass
measurements. These estimates are important in research
on drugs aimed at reducing body mass, or improving
metabolic parameters, or both [11, 15].
One possible approach is to assume that the input
function has a prespecified functional form, parametrised
with a small number of parameters. Examples of functions
used for this purpose include exponentials [37] and inverse
Gaussians [7]. In this paper, we consider non-parametric
methods that do not make strong assumptions about the
form of the input.
When the dynamics are linear, established estimation
methods exist [8, 37]. These methods rely on being able to
express the input–output relationships as convolution
integrals, something that is possible for linear systems
only. Additionally, in many cases the linear input-estima-
tion problem can be reduced to solving a quadratic opti-
misation problem [37]. In contrast, estimation in nonlinear
systems is a more difficult problem. While many poten-
tially useful methods exist in the engineering and statistical
literature, typical engineering applications have densely
sampled data, and these methods are not necessarily a good
fit for PKPD applications. Thus, their applicability needs to
be assessed on a case-by-case basis.
In this paper, we give a rigorous definition of the input-
estimation problem for nonlinear systems, and suggest
methods and software to solve the problem. Two case
studies are presented, using different choices of algorithms
to illustrate the methods and serve as a starting point for
discussions.
Problem specification
We consider models of the form:
dxðtÞ
dt
¼ fðt; xðtÞ; uðtÞÞ ð1Þ
yðtÞ ¼ gðt; xðtÞ; uðtÞ; vðtÞÞ ð2Þ
xðt0Þ ¼ x0 ð3Þ
where t 2 R is time, xðtÞ 2 Rdx is the system state, uðtÞ 2
Rdu is the input function to be estimated, yðtÞ 2 Rdy are the
measured quantities, t0 2 R is the initial time and x0 2 Rdx
is the initial state. The function f : R Rdx  Rdu 7!Rdx is
the right-hand side of the system of ODEs, and g :
R Rdx  Rdu  Rdv 7!Rdy is the measurement equation,
which has an extra variable vðtÞ 2 Rdv representing the
measurement noise. The dimensionalities dx, du, dy and dv
can take any integer values. The functions xðtÞ, uðtÞ, yðtÞ
and vðtÞ may have constraints, for example to exclude
negative values. fðÞ is assumed to satisfy the technical
requirements for the system of ODEs to have a unique
solution. No further assumptions on fðÞ and gðÞ are made,
although in practice, some estimation methods may have
additional requirements such as differentiability. In par-
ticular, fðÞ and gðÞ can be nonlinear. If they are linear,
standard methods exist for input estimation [8, 37]. The
measured quantities yðtÞ are sampled at a finite set of time
points ti, i 2 f1; . . .; ng. The set of sampled measurements
is denoted y1:n.
The aim is to estimate uðtÞ given a set of measurements,
y1:n. To make this problem well-posed, it is necessary to
impose additional assumptions on the input function. To
see this, consider a maximum likelihood estimator, that
gives the estimated input u^ðtÞ as:
u^ðtÞ ¼ argmin
uðtÞ
ED ð4Þ
where ED is the negative log likelihood function. Since uðtÞ
is an arbitrary function, and therefore infinite-dimensional,
it cannot be uniquely determined from a finite set of
measurements. This can be remedied by adding a regu-
larisation term EW , that penalises unnecessarily complex
solutions. The estimator can now be written as:
u^ðtÞ ¼ argmin
uðtÞ
ED þ sEWð Þ ð5Þ
where s is a regularisation parameter that controls the
trade-off between data fit and regularity [37].
This can also be interpreted as a Bayesian inference
problem, where the aim is to determine the posterior
distribution:
pðuðtÞjy1:nÞ ¼
pðy1:njuðtÞÞpðuðtÞÞ
pðy1:nÞ
ð6Þ
where pðy1:njuðtÞÞ is the likelihood, pðuðtÞÞ is the prior,
and pðy1:nÞ is the model evidence, which is constant for a
given dataset. By identifying ln pðy1:njuðtÞÞ ¼ ED and
ln pðuðtÞÞ ¼ sEW , it can be seen that Eq. (5) gives the
Maximum a Posteriori (MAP) estimate. An advantage of
the Bayesian interpretation is that it is possible to calculate
Fig. 1 The input estimation problem: given measurements and
known system dynamics, estimate the input function without mod-
elling its generating process
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other statistical quantities of interest, such as mean or
median estimates as well as credible intervals.
Together with the model and the data, the problem can
be specified by the following components:
– Choice of prior for uðtÞ, or equivalently, choice of
regularisation term. This encodes the prior assumptions
about the shape of the input function.
– Functional representation. In practice, the input func-
tion uðtÞ has to be represented using a finite set of
parameters. Therefore, a choice of basis for the input
function must be made.
– Desired statistical quantities. Is a MAP estimate enough
or are other quantities such as credible intervals
desired?
We will now describe these three components in more
detail.
Choice of prior for uðtÞ
In this section, priors for scalar input functions are dis-
cussed. For vector-valued input functions, priors can be
independently assigned to each component, as long as they
are assumed to be a priori independent. Assigning priors
jointly over all components is not discussed in this paper.
For scalar input functions u(t), a common choice of prior
is to penalise the first or second derivative of the function
in order to avoid unnecessarily oscillatory functions [37,
p. 87]. If the function is defined in the interval [a, b], the
unnormalised log prior becomes
ln pðuðtÞÞ / s
Z b
a
dju
dtj
 2
dt ð7Þ
Typically, here j is set to 1 or 2.
In a Bayesian setting, the prior penalising the jth
derivative can be interpreted as defining a special case of a
Gaussian process [33]. This is a stochastic process whose
finite-dimensional marginal distributions are Gaussian, and
it is completely determined by a mean and a covariance
function. The theory of Gaussian processes provides a
flexible framework for defining priors over functions.
However, this approach does not seem to have been
employed in drug discovery modelling to any significant
extent.
Another choice for scalar functions is to use the entropy
of a discrete-time version of the input uk with Ne steps:
ln pðuðtÞÞ / s
XNe1
k¼0
uk ln
uk
mk
ð8Þ
where mk is a baseline value that can be set to the average
of the nearest neighbours [20]. Conceptually, this approach
prefers functions where the function’s value at each time
point is similar to its neighbours.
Functional representation of uðtÞ
For notational convenience, this section discusses scalar-
valued functions u(t) only. When the input function is
vector-valued, each component can be represented using
the techniques described below.
To represent the input function using a finite set of
parameters, one can select a set of basis functions BiðtÞ and
write the input function as a linear combination of these:
uðtÞ ¼
XNB1
i¼0
hiBiðtÞ ð9Þ
Once a choice of basis has been made, recovering the input
function is equivalent to recovering the coefficients hi.
Perhaps the simplest choice of basis is to represent the
function as a piecewise constant function, as done in [29].
These functions are very cheap to evaluate. On the other
hand, the resulting staircase-like functions have to be
defined on a relatively dense grid to represent the actual
function well. This makes for a high-dimensional estima-
tion problem which can cause computational difficulties.
A convenient basis for a zero-mean Gaussian process
u(t) is given by the Karhunen–Loe`ve expansion [24]. This
method computes a set of basis functions such that their
coefficients will be independent zero-mean Gaussian ran-
dom variables. A good approximation can be obtained by
only retaining the basis functions contributing the most to
the input function. This can be viewed as a dimensionality-
reduction method. The fact that the coefficients are
uncorrelated can make it easier to efficiently use sampling-
based estimation methods. More formally, assume that the
process is defined in the interval [a, b] and has a covari-
ance function k(s, t). If the functions /iðtÞ and values ki
satisfy the eigenvalue problem:Z b
a
kðs; tÞ/iðsÞ ds ¼ ki/iðtÞ ð10Þ
then the process can be represented by:
uðtÞ ¼
X1
i¼0
hi
ﬃﬃﬃﬃ
ki
p
/iðtÞ ð11Þ
where the coefficients hi are independent zero-mean
Gaussian random variables with unit variance. By setting
BiðtÞ ¼
ﬃﬃﬃﬃ
ki
p
/iðtÞ and keeping the basis functions with the
NB largest eigenvalues, the prior can be placed on a finite
number of coefficients rather than on the function itself,
effectively transforming the input estimation problem to a
parameter estimation problem.
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In [28], the Karhunen–Loe`ve expansion is given for
penalisation of the first and second derivatives of the input
function, and applied to determining the input to a linear
system. For these priors, the basis functions do not depend
on the regularisation parameter. This is important since the
regularisation parameter is usually unknown and has to be
estimated from the data.
The Karhunen–Loe`ve expansion assumes that the input
function starts at 0. When penalising the second derivative,
the derivative too starts at 0. To allow functions to start at
arbitrary values, a constant or a linear term can be added.
Alternatively, splines can be used [5]. Just as piecewise
constant functions, they are non-zero only in a limited
interval. They can be computed efficiently, can be made
differentiable to an arbitrary degree, and can represent
realistic-looking functions using relatively few parameters.
Desired statistical quantities
In classical regularisation theory, the quantity of interest is
the penalised maximum likelihood, given by Eq. (5). From
a Bayesian perspective, this is the MAP estimate. One
might also be interested in the mean input function, as well
as pointwise 95 % credible intervals. The latter is impor-
tant for determining the uncertainty of the estimate.
Estimation algorithms
MAP estimates can be obtained by optimising Eq. (5).
Algorithms for optimisation in dynamical systems are
studied in the field of optimal control.
When quantities other than MAP are of interest, infer-
ence methods such as Markov Chain Monte Carlo
(MCMC) approaches can be employed [6]. Although not
explored here, it would also be possible to use other sam-
pling methods such as Sequential Monte Carlo [9] or
analytical approximations such as Variational Bayesian
methods [3].
Another estimation decision is how to select the regu-
larisation parameter s. The discrepancy criterion suggests
selecting s so that the sum of squared residuals is equal to
the expected sum of squared distances between the true
function and the measurements. In ordinary and gener-
alised cross-validation, measurements are left out from the
estimation procedure, and the ability to predict these left-
out measurements is assessed. For linear Gaussian prob-
lems, it is possible to derive analytical maximum-likeli-
hood criteria for s [35]. In the L-curve approach [18], a
MAP estimate is calculated for a large number of values for
s, and the data and regularisation cost terms ED and EW are
plotted against each other. For a low s, the data fit will be
almost perfect and the data cost will be almost zero.
Conversely, for high s, the input function is forced to
follow the regularisation criterion, and the regularisation
cost will approach a minimum value. Between these
extremes, there is a characteristic corner in the plot, where
there is a reasonable trade-off between data fit and regu-
larity. In the Bayesian paradigm, s can be treated as an
additional parameter, and can be estimated together with
the basis function coefficients.
Optimal control-based methods
The aim of optimal control is to select the input to a
dynamical system that minimises some cost function. Here,
the cost function is the negative log posterior. The opti-
misation problem can be formulated in multiple ways [4,
32].
In single shooting, only the parameters describing the
input function are included as decision variables in the
optimisation problem. The log posterior for a given input
function is calculated by solving the system of differential
equations using a numerical ODE solver. This is the most
straightforward method.
In multiple shooting, the time course of the system is
divided into a number of sub-intervals. For each such sub-
interval, the system of ODEs is solved numerically. The
input function parameters as well as the state variables at
the start of each interval are included as decision variables.
Constraints are added to the problem to ensure that the
resulting trajectories are continuous. This results in an
optimisation problem that is larger than in single shooting,
but it tends to be sparser and less non-linear.
In collocation methods, no ODE solvers are used.
Instead, the dynamic model is included in the form of
equality constraints in the optimisation problem. The time
course of the system is divided into a number of sub-in-
tervals. In each sub-interval, the state trajectories are
approximated by low-order polynomials. A small number
of collocation points are selected in each interval, and
constraints are added to ensure that the solution of the
system of ODEs is satisfied at these points. The input
function parameters as well as the state variables at the
start of each interval and at all collocation points are
included as decision variables. Additional constraints are
added to ensure that the state trajectory is continuous. This
results in an even larger optimisation problem than multi-
ple shooting, but it tends to be even sparser and less non-
linear.
Many optimisation methods rely on gradients and Hes-
sians of the objective function. A straightforward way to
compute these is to use finite differences. However, this
can be inaccurate and slow, especially in high dimensions.
A powerful alternative is to use automatic differentiation,
where gradients are automatically computed by applying
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the chain rule of calculus to the objective function [31].
For numerical ODE solvers, it is also possible to solve the
sensitivity equations to obtain gradients [2]. For input-es-
timation problems, a combination of these two methods can
be used.
An advantage of optimal control-based methods is that
they can be very fast, even for high-dimensional functional
representations such as piecewise constant functions on a
dense grid. It is easy to include extra constraints, which is
helpful in avoiding unphysical answers, such as negative
concentrations. The main disadvantage is that they can
only provide MAP estimates. It is therefore hard to assess
the uncertainty of the estimate.
Markov chain Monte Carlo (MCMC)
Most quantities of interest in Bayesian inference cannot be
computed in closed form. One way to overcome this is to
use Monte Carlo methods [34]. Let h be the vector of
parameters determining the function uðtÞ, which can
include the basis function coefficients, the regularisation
parameter, and other parameters. The idea is that the pos-
terior pðhjyÞ can be approximated by a large number of
samples hðiÞ drawn from it. This can, somewhat informally,
be represented by:
pðhjyÞ  1
N
XN1
i¼0
d
hðiÞ ; h
ðiÞ  pðhjyÞ ð12Þ
where d
hðiÞ is the Dirac function centred on h
ðiÞ. Using these
samples, any quantity of interest can be calculated by
simple arithmetic. However, drawing samples from the
posterior is in itself a non-trivial problem. Markov Chain
Monte Carlo methods solve this by constructing a Markov
chain such that its samples marginally come from the
correct distribution. The Metropolis–Hastings algorithm is
one of the most general MCMC methods [19, 27]. At each
time index i, a new sample hðiÞ is drawn using the following
algorithm:
1. Propose a new sample h0 using an arbitrary proposal
distribution pðh0jhði1ÞÞ.
2. Calculate the Metropolis–Hastings ratio A:
A ¼ min 1; pðh
0jyÞpðhði1Þjh0Þ
pðhði1ÞjyÞpðh0jhði1ÞÞ
 !
3. With probability A, set hðiÞ ¼ h0. Otherwise, set
hðiÞ ¼ hði1Þ.
It can be shown that the resulting sequence hðiÞ will
asymptotically be marginally distributed according to
pðhjyÞ. Most MCMC methods in use can be shown to be
special cases of the Metropolis–Hastings algorithm. The
parameters can be updated either one at a time, or several at
once. For a good introduction to MCMC, see [6] and [13].
In some cases, it is possible to sample from some of the
parameters conditional on the other ones. This typically
happens when conjugate priors are used, which are priors
that have the same functional form as their corresponding
posteriors. As an example, when Karhunen–Loe`ve basis
functions are used, their coefficients are normally dis-
tributed with a precision equal to the regularisation
parameter. If the regularisation parameter is assigned a
Gamma distribution prior, it can be shown that its distri-
bution conditioned on the coefficients of the basis functions
is also a Gamma distribution. Since efficient methods exist
for sampling from Gamma and other standard distributions,
this can be used to propose new parameter values. By
inserting this proposal into the Metropolis–Hastings ratio,
it can be shown that these proposals will always be
accepted. This sampling method is called Gibbs
sampling [6].
MCMC methods have the advantage that they can
handle arbitrary models and estimate any kind of statistical
quantity, including credible intervals. The downside is that
they can be slow, since a large number of samples may
have to be generated. Their performance can depend crit-
ically on the choice of proposal distribution. For high-di-
mensional functional representations, finding a proposal
distribution that gives acceptable performance can some-
times be challenging.
One possible approach to construct good proposal dis-
tributions is to use Riemannian manifold methods [14]. In
these methods, a metric tensor is defined that describes the
local geometry of the target distribution. This can be used
to construct proposals that automatically make larger steps
in the directions for which the distribution changes slowly.
In [14], it is suggested to use the sum of the Fisher infor-
mation matrix and the negative Hessian of the log prior as a
metric tensor. The simplest manifold method is the Sim-
plified Manifold Metropolis-Adjusted Langevin Algorithm
(SMMALA). In SMMALA, the new sample h0 is proposed
from a Gaussian distribution with mean l and covariance
C:
l ¼ hði1Þ þ 1
2
2G1 hði1Þ
  d ln pðhjyÞð Þ
dh

h¼hði1Þ
ð13Þ
C ¼ 2G1 hði1Þ
 
ð14Þ
where GðÞ is the metric tensor and  is a user-specified
scale factor. An intuitive motivation for SMMALA is that
it proposes values from a quadratic approximation of the
log target distribution. The required gradients can be
obtained by using automatic differentiation and solving the
corresponding sensitivity equations.
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It is also possible to mix proposals, for example by using
different updating mechanisms for different parameters.
This is exemplified here in Case Study 2.
Even though the samples from the Markov chain are
drawn from the desired distribution asymptotically, the
initial part of the chain may be non-representative and
should be discarded. Various methods have been proposed
to assess whether convergence to the desired distribution
has been achieved [25]. In Geweke’s method, the mean and
variance from different segments of the chain are com-
pared [12]. The Gelman–Rubin method compares the
within-chain and between-chain variance of several Mar-
kov chains initialised in different parts of the parameter
space [10]. In the Raftery–Lewis method, the user can
specify that quantiles of particular parameters should be
estimated to a given accuracy. By analysing statistics of
where the parameters exceed these quantiles, an estimate of
the number of samples to discard can be obtained [30].
Assessing the number of samples required for an accu-
rate estimate is non-trivial. Since the samples generated by
the Markov chain are correlated, N samples from the chain
give a less accurate estimate than N independent samples.
The previously mentioned Raftery–Lewis method can
provide an estimate for the required number of samples.
The effective sample size (ESS) is another way to assess the
quality of the samples. It is a rough estimate of the number
of independent samples required to obtain the same
approximation error as the samples from the Markov chain
and can be calculated from the autocorrelation of the
generated samples [14, Sect. 7.1].
Previous work
Many previously used nonparametric input-estimation
methods can be described using the framework presented
above:
Verotta [37] gives a good overview of classical input-
estimation (deconvolution) methods for linear systems. As
a choice of prior, two approaches are suggested: either
using the norm of the first or second derivative of the input
function, or parametrising the input function with few
enough parameters so that the problem becomes well-
posed without the use of a prior. As basis functions,
piecewise constant and spline functions are suggested.
Obtaining point estimates using optimisation techniques is
discussed. Suggested methods to assess uncertainty esti-
mates include quadratic approximations around the MAP
estimate and bootstrapping. The methods are tested on
pharmacokinetic examples as well as an example involving
estimating the secretion rate of lutenizing hormone.
Magni et al. [26] employ MCMC techniques to do full
Bayesian inference using piecewise constant basis
functions and a prior penalising the first or second
derivative, and use this to estimate insulin secretion rate
after a glucose stimulus.
Pillonetto et al. [29] suggest penalising the first deriva-
tive of the logarithm of the input function to handle non-
negativity constraints. Piecewise constant basis functions
are used, and full inference is done using MCMC. The
method is applied to estimate lutenising hormone secretion
rate as well as to pharmacokinetic problems.
Pillonetto and Bell [28] suggest using Karhunen–Loe`ve
basis functions with various priors. Since their examples
are unconstrained linear Gaussian models, full inference
can be done analytically without resorting to sampling
methods. However, MCMC is used to estimate the regu-
larisation parameter. The methods are tested on synthetic
test functions.
Hattersley et al. [20] use an entropic prior together with
piecewise constant basis functions. MAP estimates are
obtained using a Sequential Quadratic Programming opti-
misation method. The method was used to estimate the
production rate of free light chains in multiple myeloma
patients.
Case studies
Here, various input-estimation approaches are illustrated
using two case studies, fully specified in the supplement.
Both optimal control-based and MCMC methods were
implemented on top of CasADi, a framework for numeric
optimisation [1]. This software can compute gradients and
Hessians by automatic differentiation, and has interfaces to
the ODE solver package SUNDIALS [21] together with
the optimisation software IpOpt [38]. CasADi is imple-
mented in C??, but at the time of writing, the recom-
mended way to use it is to call it from Python.1 All the code
for the case studies was written in Python 2.7, using
CasADi version 2.4.1 for computing log posteriors, gradi-
ents and metric tensors as well as for performing optimi-
sation with IpOpt. The code can be obtained at www2.
warwick.ac.uk/fac/sci/eng/research/biomedical/impact/ear
lystageresearcher/magnustragardh/.
Case Study 1
In this case study, input-estimation methods were applied to
a dataset from a previously published study [22]. The pur-
pose of the studywas to characterise the pharmacokinetics of
eflornithine, a drug used to treat Human African Try-
panosomiasis. Using data from intravenous administration, a
1 www.python.org.
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nonlinear 3-compartment model (Fig. 2) could be fitted to
the data:
dCp
dt
¼ uðtÞ
Vc
 CL
Vc
þ Q
Vc
 
Cp þ Q
Vc
Ct  kon  Cp
 Rmax
Vc
 Cb
 
þ koff  Cb
ð15Þ
dCt
dt
¼ Q
Vt
Cp  Q
Vt
Ct ð16Þ
dCb
dt
¼ kon  Cp  Rmax
Vc
 Cb
 
 koff  Cb ð17Þ
where Cp, Ct and Cb are the drug concentrations in the
central, peripheral and binding compartments, and Vc, Vt,
CL, Q, kon, koff and Rmax are parameters, defined in the
original paper and in the supplement. The drug concen-
tration in the central compartment Cp was measured. When
the drug is given intravenously, the input u(t) is an impulse.
When the same drug is given orally, the input u(t) describes
the absorption rate of the drug. Using the model and con-
centration data from experiments when the drug was
administered orally, the absorption rate could be
determined.
In the original article, this was done by fitting a
smoothing spline to the concentration measurements, and
directly inverting the system of ODEs. While this approach
yielded satisfactory results, it is somewhat simplistic. Since
it enforces smoothness on the output function rather than
on the input, it is difficult to determine what assumptions
about the input function are actually being made. Addi-
tionally, no attempt was made to assess estimation
uncertainty.
For this paper, the input-estimation methods described
previously were applied to two representative time series:
one for a low dose of 20 mg/kg and one for a high dose of
1500 mg/kg.
Penalisation of the second derivative, as in Eq. (7) was
chosen as a prior. Two input parametrisations were inves-
tigated: Cubic B-splines with breakpoints at the
measurement times, and a piecewise constant function,
discretised to 100 uniformly distributed intervals. Both
MAP estimates and pointwise means and 95 % credible
intervals were sought. To this end, optimal control methods
as well as MCMC were used.
The time series are characterised by an early phase,
where the plasma concentration has a large peak and the
sampling is relatively dense, and a late phase, where the
plasma concentration has declined and sampling is sparser
(Fig. 3). To capture the initial peak, the amount of regu-
larisation cannot be too large. On the other hand, too little
regularisation can cause unrealistically large uncertainty in
the latter sparsely sampled part. One way to mitigate this is
to apply the prior to the logarithm of the input function
rather than to the input function itself. This has the added
benefit of automatically ensuring that the input function is
always non-negative. In the sequel, this will be referred to
as the ‘‘log-scale model’’, while penalising the function
itself will be referred to as the ‘‘linear-scale model’’.
As a first step, a suitable value for the regularisation
parameter s was determined using the L-curve
approach [18]. To investigate the sensitivity to s, the sub-
sequent estimation was run using three different values:
one at the ‘‘knee’’ of the curve, and one on either side of
this. The resulting estimates were qualitatively similar for
all three values. Fig. 4 shows a typical L-curve.
In summary, the following analyses were performed:
– MAP estimation using the cubic spline model.
– MAP estimation using the piecewise constant model.
– Full Bayesian estimation by MCMC using the cubic
spline model.
All analyses were performed for both time series, and for
both the linear- and the log-scale models. MCMC estima-
tion turned out to be too inefficient when the number of
parameters significantly exceeds the number of measure-
ments. Therefore, MCMC estimation was not used for the
piecewise constant model.
For the optimal control-based methods, single shooting
was used for the spline model, since this made it easy to
reuse the code for the MCMC estimation. For the piecewise
constant model, single shooting was too inefficient and was
replaced by collocation.
For MCMC, a simple component-wise Gaussian ran-
dom-walk Metropolis–Hastings algorithm was used. In this
method, each parameter is updated individually, using a
Gaussian proposal density centred on the current value.
The variance of the proposal density was tuned during trial
runs to maintain the acceptance rate between 0.2 and 0.5,
and hence keep it reasonably close to optimal values [6,
Sect. 4.2]. The tuning was performed by monitoring the
acceptance rate every 100 iterations, and modifying the
proposal variance if the acceptance rate was not in the
Fig. 2 Three-compartment model for Case Study 1. The aim is to
estimate the function u(t) given measurements of Cp
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Fig. 3 Estimated absorption rates, predicted plasma concentrations,
and plasma concentration measurements for low and high doses with
both log- and linear-scale models in Case Study 1. All estimates are
calculated using the mid value for the regularisation parameter. The
shaded regions are 95 % credible intervals. MAP estimates were
obtained with single shooting, and mean and credible interval
estimates were obtained with MCMC
Fig. 4 Example L-curve
obtained for the low-dose
dataset in Case Study 1. Three
values for s were selected to be
used in the subsequent analysis
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range 0.2–0.5. The Markov chains were initialised to the
MAP estimate given by the optimal-control techniques.
15,000 samples were drawn for each analysis.
Obtaining MAP estimates is in general computationally
cheap. For the linear-scale model, even the 100-dimen-
sional piecewise-constant model could be solved using
collocation methods in a matter of seconds on an ordinary
workstation. On the other hand, these methods were unable
to find a solution to the log-scale version of the piecewise-
constant model. Therefore, all results for the log-scale
model were obtained using splines. MCMC is considerably
more expensive—drawing 15,000 samples requires 20–30
min on the test machine. One reason for the long running
time is that the parameters are updated one at a time, and
the ODE solutions have to be recomputed for every update.
Updating several parameters jointly would be more effi-
cient, but finding good proposals for joint updates can be
challenging. Methods for doing this are explored in Case
Study 2.
The ESS, as defined in ‘‘Estimation Algorithms’’ section,
was used as a measure of the quality of the samples. In par-
ticular, the ESS of the bioavailabilitywasmonitored, as it was
considered to be the most important quantity. Typical ESS
values ranged from 300 to 2000 samples. The notable ex-
ception was the linear-scale model with the low dose, where
the quality of the samples from the Markov chain was very
poor despite the large number of samples and extensive tun-
ing. Here, the typical ESSwas around 10 samples. The results
from that analysis are therefore very uncertain.
From Fig. 3, it can be seen that for the high dose, the
linear-scale model gives an underprediction of the initial
peak at around 350 min. During 900–1400 min, the sparse
sampling causes the uncertainty of the plasma concentra-
tion to drop below 0, clearly an unphysical result. The log-
scale model appears to capture the peak better and keeps
the uncertainty within reasonable values. For the low dose,
the poor mixing of the Markov chain makes it hard to make
any conclusions about the linear-scale model. The log-scale
model appears to capture the data well.
In Fig. 5, the bioavailability estimates are centred
between 0.3 and 0.4. For comparison, in [22] the bioavail-
ability was estimated to be 0.30 for the low dose and 0.38 for
the high dose. Thewide distribution of the linear-scalemodel
with low dose can probably be attributed to the small ESS.
For the high dose, the log-scale model predicts a slightly
higher bioavailability than the linear-scale model. This is
because the log-scale model is better at capturing the initial
peak, which is the main contribution to bioavailability.
Case Study 2
The data in this case study come from a drug-discovery
project where the effect of two optimised monoclonal
antibodies targeting fibroblast growth factor receptor
(FGFR) 1c (R1c mAb opt1 and R1c mAb opt2) was studied
by measuring energy intake and body mass over time [11].
The parent R1c mAb has previously been shown to cause
profound body weight and body fat loss due to decreased
food intake (with energy expenditure unaltered), thereby
improving glucose control in diet-induced obese (DIO)
mice [23]. Thus, inhibiting R1c has become an attractive
target for developing novel therapies against obesity and
diabetes. However, different R1/R1c mAbs have been
shown to decrease body weight solely due to hypophagia or
via a combined effect on both food intake and energy
expenditure [23, 36, 39], thus demonstrating the impor-
tance of taking both caloric intake and expenditure into
account when defining mechanisms for weight-loss thera-
pies. It is of great interest to be able to estimate energy
intake without having to measure it directly, since methods
for measuring energy intake can be unreliable, or expen-
sive, or both [15]. The objective of this analysis was to
investigate the possibility of estimating the energy intake
from body-mass measurements alone.
The study consisted of seven groups of DIO mice: one
vehicle group, and three groups of each of the two inves-
tigated substances, R1c mAb opt1 or R1c mAb opt2
administered as a single subcutaneous injection with doses
of 0.3, 3 or 10 mg/kg. Each group comprised four mice,
and energy intake was measured per group. Body mass was
measured per individual, and group averages computed.
Measurements were taken 9 days before treatment, and
subsequently once per day or once every 2 days, up to 30
days after treatment. The analysis was performed using
Fig. 5 Kernel density estimate of the posterior of the oral bioavailabilities in Case Study 1. The solid line represents the mean, and the dashed
lines show the 95 % credible interval
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group means. All animal experiments were approved by the
Gothenburg Ethics Committee for Experimental Animals.
The relationship between energy intake and body mass
was characterised using the semi-mechanistic model of
Guo and Hall [16, 17]. This model divides the total mass
into fat mass (FM) and fat-free mass (FFM):
dFFM
dt
¼ a
a  qFFM þ qFM
ðEI  EEÞ ð18Þ
dFM
dt
¼ 1
a  qFFM þ qFM
ðEI  EEÞ ð19Þ
where EI is the energy intake, EE is the energy expendi-
ture, qFFM and qFM are the densities of fat-free and fat
tissue, and a is the Forbes function, relating changes in fat
mass to changes in fat-free mass, empirically given by:
a ¼ q1 þ q2  eq3FM ð20Þ
Furthermore, the energy expenditure is given by:
EE ¼ðK þ bDEI þ ðcFFM þ kÞ  FFM þ ðcFM þ kÞ  FM
þ gFFM  a  g  EI þ gFM  g  EIÞ=ð1þ gFM  gþ gFFM  a  gÞ
ð21Þ
where K is a constant thermogenesis parameter, DEI is the
difference between the energy intake and a standard ref-
erence intake (12 kcal/day), b is a scaling parameter, gFFM
and gFM are biochemical efficiencies for fat and protein
synthesis, cFFM and cFM represent the relationship between
metabolic rate and mass, and g ¼ 1=ða  qFFM þ qFMÞ. The
function k represents physical activity and could be cap-
tured by the empirical equation:
k ¼ k0 þ k3 þ k1  k2  t  e
k2t ift 0
k0 otherwise
(
ð22Þ
where ki, i 2 f0; 1; 2; 3g were estimated from data for each
dose group and t ¼ 0 is the start of the treatment. These
parameters are not to be confused with the eigenvalues ki
in Eq. (11). All other model parameters were literature
values, as used in [11] and defined in the supplement.
As choice of prior, the first derivative of the energy intake
was penalised, which is equivalent to modelling the energy
intake as a randomwalk. For the body-massmeasurements, a
proportional 0.5 % measurement noise was assumed.
The input functions were represented using Karhunen–
Loe`ve basis functions [28]. Twenty basis functions were
used, as it was found that adding more did not significantly
influence the estimates. A constant term, which was not
penalised, was added to allow the energy intake to start at a
nonzero value. The regularisation parameter was treated as
an unknown parameter, and estimated jointly with the basis
function coefficients. It was assigned a Gamma distribution
prior, which is a conjugate prior to the inverse variance of
the basis function coefficients. This makes it possible to
estimate it using Gibbs sampling. The Gamma distribution
was assigned a shape parameter of 0.001 and a rate
parameter of 0.001, in order to make the prior flat and thus
to avoid making strong a priori assumptions about the
parameter value.
The sampling process was carried out as follows:
1. A good starting point for MCMC sampling was
determined. This was done by fixing the regularisation
parameter to a high value, and optimising the log
posterior with respect to the basis coefficients.
2. MCMC sampling was done by alternating between the
following updates:
(a) Updating the regularisation parameter using
Gibbs sampling.
(b) Jointly updating the coefficients of the basis
functions using SMMALA.
The computational bottleneck is the calculation of the
Jacobian of the predicted body mass with respect to the
basis coefficients, which is necessary in order to evaluate
the metric tensor. To obtain an efficient algorithm, it is
highly desirable to use sampling techniques which min-
imise the number of metric tensor evaluations. The sam-
pling method used in 2(a) and 2(b) performs well since all
basis coefficients are updated jointly, requiring only a
single metric tensor computation per iteration. The regu-
larisation parameter is cheap to update, since the log target
and the metric tensor can be updated without recalculating
the Jacobian.
In most of the measured time-series, the estimated
inputs agree reasonably well with the data (Fig. 6). The
main difficulty is the rapid decrease in energy intake seen
around t ¼ 0, which is hard to capture with a random-walk
model. It can be noted that the uncertainty in the energy
intake is considerably greater than in the body mass. This
can be expected, since the model acts as a lowpass filter:
rapid changes in energy intake do not cause equally rapid
changes in body mass. There are therefore multiple energy
intake profiles that would result in similar body mass
measurements. A consequence of this is that fast oscilla-
tions are not captured reliably. Still, the method is honest in
that it correctly gives an uncertainty region that includes
cFig. 6 Measured and estimated energy intake and body mass for all
datasets in Case Study 2. The body-mass measurements (circles) were
used for estimation, while the energy-intake measurements (triangles)
are not known to the estimation algorithm and are plotted for
comparison with the estimates. The shaded regions are 95 % credible
intervals
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most points. It can also be noted that the uncertainty in the
energy intake as well as in the body mass is larger during 8
days prior to treatment where no measurements are taken.
It is an attractive feature of these methods that such
uncertainty is automatically accounted for.
For comparison, a similar sampling scheme was tested
on a single time-series, where the basis coefficients were
jointly updated using the Random Walk Metropolis–Hast-
ings (RWMH). The proposal covariance matrix was
selected by computing the metric tensor at the MAP esti-
mate, and scaling this to get an acceptance rate around
20–30 %. RWMH can draw samples approximately 10
times faster than SMMALA, since it does not need to
evaluate the Jacobian. However, in terms of effective
samples per second, SMMALA gives better performance,
since its samples are considerably less correlated (Fig. 7).
Furthermore, several trial runs had to be made to find a
good scaling factor for RWMH, something which has to be
done separately for each time-series. In contrast,
SMMALA required no manual tuning. Running time and
median effective sample size are shown in Table 1.
A weakness in the current work is that the measured
energy intake was used to estimate the physical activity
parameters ki, i 2 f0; 1; 2; 3g. Since the purpose here was
to evaluate the possibility of estimating the energy intake
given that the system dynamics are known, this was con-
sidered acceptable. For the methods to be useful in
experiments where the energy intake is not measured, it
would be necessary to characterise the vehicle and drug
effect on the physical activity by a generic model.
Discussion
Both case studies show that, in terms of computational
speed, MAP estimates can be obtained quickly for these
kinds of models. Obtaining full posteriors in a reasonable
amount of time is considerably more difficult. Case Study 1
shows that naive application of MCMC methods does not
perform well in certain cases. SMMALA can be a good
default choice, since it can efficiently update several
parameters jointly, and does not require any user-specified
tuning. It could also be worthwhile to investigate more
advanced MCMC proposals, such as Hamiltonian Monte
Carlo and Riemannian Manifold Hamiltonian Monte Carlo
methods [14].
An alternative way to obtain estimates is to make mul-
tiple MAP estimates using bootstrapping. Note, however,
that this will give a frequentist estimate of estimator vari-
ance rather than of uncertainty in the Bayesian sense. Great
care has to be taken when interpreting and comparing
uncertainty estimates from different methods.
It may also be worthwhile to investigate other
parametrisations. Although the Karhunen–Loe`ve expansion
has appealing theoretical properties, it has the disadvantage
that all basis functions are non-zero at all time points,
making it necessary to sum all of them when evaluating at
a single time point. They also make it difficult to impose
non-negativity constraints.
The most principled and automated way to estimate the
regularisation parameter is the Bayesian method of treating
it as an additional random variable to be estimated from the
Fig. 7 Representative MCMC
traces for a parameter (R1c
mAb opt1, 10 mg/kg, coefficient
6). It can be clearly seen that
SMMALA traces explore the
parameter space more
efficiently
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data. However, for certain problems this method can have
robustness issues. The L-curve method is an alternative,
but it is far from ideal in terms of usability, since it requires
the user to plot and manually select a value from the curve.
A disadvantage of using a linear-scale input model is
that it does not rule out negative energy intakes. It is
possible to impose non-negativity constraints by using a
log-scale input model, as in Case Study 1. However, such a
model may be hard to justify in certain cases, and it makes
it more difficult to find efficient sampling methods.
Another way to impose constraints would be to simply
reject all proposed input functions that drop below zero.
This could be reasonably efficient when only a small por-
tion of the unconstrained distribution is below zero. In
other cases, it could lead to prohibitively large rejection
rates. A pragmatic approach is to use the unconstrained
results as is, acknowledging that it is just an approximation.
This is what has been done in Case Study 2.
In the case studies, uncertainties in the system model are
not taken into account. Adding this could improve the
statistical soundness and give more realistic estimates. This
could be done by including uncertain system parameters in
the estimation problem, estimating them jointly with the
input function. Although it may be computationally
expensive, it would not require any conceptual changes to
the methods. It may also be possible to embed these
methods in a non-linear mixed effects (NLME) framework.
CasADi has proved to be a valuable tool in that it allows
the user to easily obtain gradients and Hessians for com-
plicated functions, which can include calls to numerical
ODE solvers. The details involved in formulating and
solving the sensitivity equations are handled automatically
by the software.
Since the performance of the methods may be problem-
specific, it is important to evaluate them using multiple
datasets and models. Only then can any conclusions about
general usefulness be made.
Conclusions and future work
Numerous drug discovery deconvolution-applications have
been reported over the years, and it is evident that there is a
need for useful methods also for the more general non-
linear case, referred to as input estimation. This work
serves as a highly promising starting point for application
of input-estimation methods to problems in drug discovery:
it gives a rigorous definition of the problem, it lists main
methods and how these can be implemented, and discusses
the application of the methods to realistic case studies.
Additionally, the usefulness of CasADi for implementing
these methods has been investigated and verified.
The presented methods for optimal control for input
estimation can be recommended for use in drug discovery.
The MCMC-based methods work well in certain cases, but
they can have long running times, and care has to be taken
to make sure that the parameter space is well explored.
Further improvements would be desirable before they can
be recommended for use by non-experts.
Suggestions for future work in this area include inves-
tigating the choice of prior and basis functions. It can be of
interest to evaluate additional criteria for choosing the
regularisation parameter. Note, however, that the regular-
isation parameter does not require any special treatment
when Bayesian methods are used. Additionally, more
advanced MCMC methods can be evaluated and alternative
criteria can be considered for determining the number of
MCMC samples necessary to obtain an accurate estimate.
To gain a better understanding of the performance of
these methods, more combinations of prior choice, basis
functions and estimation methods should be evaluated on a
larger collection of input-estimation problems, ideally
including both real and simulated data. The two fully
specified problems of this paper form the base of such a
collection. Desirable properties of input-estimation meth-
ods to evaluate include:
Table 1 Running time and ESS for the time-series in Case Study 2
Dose group Method Number of samples Time (s) Median ESS Median ESS (s)
Vehicle SMMALA 5000 151.1 940.8 6.2
R1c mAb opt1 (0.3 mg/kg) SMMALA 5000 172.6 685.5 4.0
R1c mAb opt1 (3 mg/kg) SMMALA 5000 179.1 601.6 3.4
R1c mAb opt1 (10 mg/kg) SMMALA 5000 172.6 694.6 4.0
R1c mAb opt2 (0.3 mg/kg) SMMALA 5000 151.6 866.8 5.7
R1c mAb opt2 (3 mg/kg) SMMALA 5000 162.9 828.8 5.1
R1c mAb opt2 (10 mg/kg) SMMALA 5000 173.4 551.0 3.2
R1c mAb opt1 (10 mg/kg) RWMH 50,000 142.4 267.2 1.9
ESS effective sample size
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– Computational speed. The method should be fast
enough to appeal to modellers working under time
constraints.
– Usability. It should be possible for non-experts to use
the method.
– Statistical soundness. All assumptions should be rea-
sonable and explicitly stated. Sources of uncertainty
should be accounted for.
– Usefulness. The algorithm should be applicable to as
many input-estimation problems as possible.
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